metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population
versus placebo
	durvalumab alone
	PACIFIC, 2017 N Engl J Med 2017;377:1919-1929 N. Engl. J. Med. 2018; 379:2342-2350 Lancet Oncol. 2019; 20:1670-1680 Br J Cancer 2020 Dec;123(Suppl 1):18-27. World J Clin Oncol 2020 Nov 24;11(11):898-917. J Thorac Oncol 2021 May;16(5):860-867. Ann Oncol 2020 Jun;31(6):798-806. J Thorac Oncol 2020 Feb;15(2):288-293. J Natl Compr Canc Netw 2021 Feb 2;19(2):153-162. Lung Cancer 2021 Jan;151:30-38. Future Oncol 2021 Apr;17(10):1165-1184. Clin Lung Cancer. 2021 Jun 12;S1525-7304(21)00144-3 ESMO Open 2022; 7:100410-. J Clin Oncol 2022; 40:1301-1311-. NCT02125461	RCT	laNSCLC - M - all population	Durvalumab as consolidation therapy	placebo	patients with stage III unresectable NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy (consolidation therapy)	476 / 237	low	conclusif	demonstrated 32 % decrease in deaths (OS) (PE) demonstrated 48 % decrease in progression or deaths (PFS) (PE) suggested 28 % decrease in deaths (OS) (extension) suggested 45 % decrease in PFS (extension) more...
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus Standard of Care (SoC)
	durvalumab alone
	MYSTIC (D ; all population), 2020 JAMA Oncol 2020 May 1;6(5):661-674. NCT02453282	RCT	mNSCLC - L1 - all population	durvalumab	platinum-based doublet chemotherapy	first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%	374 / 372	some concern	inconclusive	no statistically significant result
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	durvalumab alone
	MYSTIC (D ; PDL1>25%), 2020 JAMA Oncol 2020 May 1;6(5):661-674. NCT02453282	RCT	mNSCLC - L1 - PDL1 positive	durvalumab	platinum-based doublet chemotherapy	first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%	163 / 162	some concern	inconclusive	inconclusive 24 % decrease in deaths (OS) (PE)
mNSCLC - L2 - EGFR mutant metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - EGFR mutant
versus osimertinib
	durvalumab plus osimertinib
	CAURAL (EXPLORATORY), 2019 J Thorac Oncol 2019 May;14(5):933-939. NCT02454933	RCT	mNSCLC - L2 - EGFR mutant	durvalumab plus osimertinib	osimertinib	Patients with EGFR T790M mutation positive locally advanced/metastatic NSCLC (stage IIIB–IV) (previous treatment 1 to >4)	14 / 15	some concern	inconclusive	no statistically significant result
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus Standard of Care (SoC)
	durvalumab alone
	ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 Clin Lung Cancer 2016; 17:232-236.e1 Ann Oncol 2020 May;31(5):609-618. NCT02352948	RCT	mNSCLC - L2 - PDL1 positive	durvalumab	standard of care : erlotinib, gemcitabine or vinorelbine	patients with PD-L1 positive locally advanced or metastatic non small cell lung cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for stage IIIB/IV locally advanced or mNSCLC;	62 / 64	some concern	suggested	suggested 37 % decrease in deaths (OS)

Study

study type

Pathology

Patients

sample sizes

ROB

Results

NCT02125461

RCT

laNSCLC - M - all population

Durvalumab as consolidation therapy

placebo

patients with stage III unresectable NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy (consolidation therapy)

476 / 237

demonstrated 32 % decrease in deaths (OS) (PE)
demonstrated 48 % decrease in progression or deaths (PFS) (PE)
suggested 28 % decrease in deaths (OS) (extension)
suggested 45 % decrease in PFS (extension)

NCT02453282

RCT

mNSCLC - L1 - all population

durvalumab

platinum-based doublet chemotherapy

first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%

374 / 372

NCT02453282

RCT

mNSCLC - L1 - PDL1 positive

durvalumab

platinum-based doublet chemotherapy

first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%

163 / 162

inconclusive 24 % decrease in deaths (OS) (PE)

NCT02454933

RCT

mNSCLC - L2 - EGFR mutant

durvalumab plus osimertinib

osimertinib

Patients with EGFR T790M mutation positive locally advanced/metastatic NSCLC (stage IIIB–IV) (previous treatment 1 to >4)

14 / 15

NCT02352948

RCT

mNSCLC - L2 - PDL1 positive

durvalumab

standard of care : erlotinib, gemcitabine or vinorelbine

patients with PD-L1 positive locally advanced or metastatic non small cell lung cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for stage IIIB/IV locally advanced or mNSCLC;

62 / 64

suggested 37 % decrease in deaths (OS)

laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

mNSCLC - L2 - EGFR mutant metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - EGFR mutant

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive